[go: up one dir, main page]

WO2010018213A3 - Spiroimidazole compounds suitable for the treatment of neurological disorders - Google Patents

Spiroimidazole compounds suitable for the treatment of neurological disorders Download PDF

Info

Publication number
WO2010018213A3
WO2010018213A3 PCT/EP2009/060514 EP2009060514W WO2010018213A3 WO 2010018213 A3 WO2010018213 A3 WO 2010018213A3 EP 2009060514 W EP2009060514 W EP 2009060514W WO 2010018213 A3 WO2010018213 A3 WO 2010018213A3
Authority
WO
WIPO (PCT)
Prior art keywords
treatment
spiroimidazole
neurological disorders
compounds suitable
compounds
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/EP2009/060514
Other languages
French (fr)
Other versions
WO2010018213A2 (en
Inventor
Roderick Alan Porter
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Glaxo Group Ltd
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Publication of WO2010018213A2 publication Critical patent/WO2010018213A2/en
Publication of WO2010018213A3 publication Critical patent/WO2010018213A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D231/18—One oxygen or sulfur atom
    • C07D231/20—One oxygen atom attached in position 3 or 5
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Neurosurgery (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The present invention relates to compounds, processes for their preparation, pharmaceutical compositions and medicaments containing them and to their use in the treatment of a condition wherein inhibition of GIyT1 would be beneficial, including neurological and neuropsychiatric disorders, in particular psychoses, dementia or attention deficit disorder.
PCT/EP2009/060514 2008-08-15 2009-08-13 Compounds Ceased WO2010018213A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB0814991.6 2008-08-15
GBGB0814991.6A GB0814991D0 (en) 2008-08-15 2008-08-15 Compounds

Publications (2)

Publication Number Publication Date
WO2010018213A2 WO2010018213A2 (en) 2010-02-18
WO2010018213A3 true WO2010018213A3 (en) 2010-05-27

Family

ID=39812139

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2009/060514 Ceased WO2010018213A2 (en) 2008-08-15 2009-08-13 Compounds

Country Status (2)

Country Link
GB (1) GB0814991D0 (en)
WO (1) WO2010018213A2 (en)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2331571B1 (en) 2008-09-18 2015-08-26 Northwestern University Nmda receptor modulators and uses thereof
CN103459379B (en) * 2011-02-21 2015-04-01 大正制药株式会社 Glycine transport inhibitor
WO2014120783A1 (en) 2013-01-29 2014-08-07 Naurex, Inc. Spiro-lactam nmda receptor modulators and uses thereof
EP3199156A1 (en) * 2016-02-01 2017-08-02 Heinrich-Heine-Universität Düsseldorf Use of glycine transporter 1 antagonists as central nervous analgesics
EA201990424A1 (en) 2016-08-01 2019-08-30 Аптиникс Инк. SPIRALACTAM MODULERS OF NMDA RECEPTOR AND THEIR APPLICATION
WO2018026798A1 (en) 2016-08-01 2018-02-08 Aptinyx Inc. Spiro-lactam nmda modulators and methods of using same
ES2972533T3 (en) * 2016-08-01 2024-06-13 Tenacia Biotechnology Hong Kong Co Ltd Spirolactam-based NMDA receptor modulators and their uses
AU2017306158B2 (en) 2016-08-01 2021-10-14 Aptinyx Inc. Spiro-lactam and bis-spiro-lactam NMDA receptor modulators and uses thereof
ES2973283T3 (en) 2016-08-01 2024-06-19 Tenacia Biotechnology Hong Kong Co Ltd Spirolactam NMDA receptor modulators and uses thereof
KR102761196B1 (en) 2018-01-31 2025-02-03 테나시아 바이오테크놀로지 (홍콩) 코., 리미티드 Spiro-lactam NMDA receptor modulators and uses thereof
US12012413B2 (en) 2019-11-11 2024-06-18 Tenacia Biotechnology (Hong Kong) Co., Limited Methods of treating painful diabetic peripheral neuropathy

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008092878A1 (en) * 2007-02-01 2008-08-07 Glaxo Group Limited Glyt1 transporter inhibitors and uses thereof in treatment of neurological and neuropsychiatric disorders

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008092878A1 (en) * 2007-02-01 2008-08-07 Glaxo Group Limited Glyt1 transporter inhibitors and uses thereof in treatment of neurological and neuropsychiatric disorders

Also Published As

Publication number Publication date
GB0814991D0 (en) 2008-09-24
WO2010018213A2 (en) 2010-02-18

Similar Documents

Publication Publication Date Title
WO2010018213A3 (en) Spiroimidazole compounds suitable for the treatment of neurological disorders
WO2009127642A3 (en) Use of lrrk2 inhibitors for neurodegenerative diseases
TN2012000428A1 (en) Bisaryl-bonded aryltriazolones and use thereof
MX2010006033A (en) 4-(4-cyano-2-thioaryl)dihydropyrimidinones and use thereof.
TN2011000466A1 (en) Substituted 2-acetamido -5-aryl-1, 2, 4- triazolones and use thereof
WO2008132139A3 (en) New heterocyclic derivatives useful for the treatment of cns disorders
MX2010002312A (en) Triazolopyridine compounds and their use as ask inhibitors.
WO2008104306A3 (en) Substituted 4-aryl-1,4-dihydro-1,6-naphthyridinamides and use thereof
PH12017500851A1 (en) Compounds and their use as bace inhibitors
SG179120A1 (en) Novel compounds
IL215910A (en) 1,2,4-triazolo[4,3-a]pyridine derivatives, pharmaceutical compositions comprising them, processes for their preparation and uses thereof for the preparation of medicaments for treating central nervous system disorders
WO2011069063A3 (en) Multicyclic compounds and methods of use thereof
WO2012096929A3 (en) Heteroaryl compounds and methods of use thereof
UA102238C2 (en) 4-(4-cyano-2-thioaryl)dihydro-pyrimidinones and use thereof
IL219160A0 (en) Novel compositions for preventing and/or treating degenerative disorders of the central nervous system
MY150931A (en) Substituted oxazolidinones and their use
UA102515C2 (en) Novel dosage form
CL2008000982A1 (en) COMPOUNDS DERIVED FROM 5-OXO-ISOXAZOL-CARBOXAMIDA; PREPARATION PROCESS; PHARMACEUTICAL COMPOSITION; PROCEDURE OF PRODUCTION OF THE PHARMACEUTICAL COMPOSITION; AND USE IN THE TREATMENT AND / OR PREVENTION OF ATEROSCLEROTIC DISORDERS, OF METABOLISM OF
MX2010002506A (en) Substituted nicotinamide compounds and the use thereof in pharmaceutical products.
TW200724532A (en) Pyrimidinecarboxylic acid derivatives and their use
WO2008092877A3 (en) 8-oxa-1, 4-diazaspiro [4,5] dec-3-en-1-yl and 1,4, 8-triazaspiro [4,5] dec- 3-en-1-yl acetamides as glyti transporter inhibitors in treatment of neurological and neuropsychiatric disorders
MX2009009361A (en) Novel dosage form.
MX2013002261A (en) Substituted n-phenethyltriazoloneacetamides and use thereof.
WO2008130321A3 (en) Novel n-tetrahydronaphtalene or 5-heterocyclyl-chromane or 8-heterocyclyl-tetrahydronaphtalene derivatives for the treatment of pain
TN2010000597A1 (en) Substituted 7-sulfanylmethyl, 7-sulfinylmethyl and 7-sulfonylmethyl indoles and use thereof

Legal Events

Date Code Title Description
NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 09781818

Country of ref document: EP

Kind code of ref document: A2